Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial

Abstract Background The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is noninferior to comparator epoetin alfa or darbepoetin alfa for two co-primary endpoints: hemoglobin (Hb) efficacy and cardiovascular (CV) safety. Methods We report the trial design, key demographic, clinical and laboratory findings, and baseline therapies of 2964 patients randomized in the open-label (sponsor-blinded) active-controlled, parallel-group, randomized ASCEND-D clinical trial. We also compare baseline characteristics of ASCEND-D patients with patients who are on dialysis (CKD G5D) enrolled in other large CV outcome trials (CVOTs) and in the most relevant registries. Results The median age of patients was 58 years, 43% were female; 67% were White and 16% were Black. The median Hb at baseline was 10.4 g/dL. Among randomized patients, 89% were receiving hemodialysis and 11% peritoneal dialysis. Among key comorbidities, 42% reported a history of diabetes mellitus and 45% a history of CV disease. Median blood pressure was 134/74 mmHg. The median weekly dose of epoetin was 5751 units. Intravenous and oral iron uses were noted in 64 and 11% of patients, respectively. Baseline demographics were similar to patients with CKD G5D enrolled in other CVOTs and renal patient registries. Conclusions ASCEND-D will evaluate the efficacy and safety of daprodustat compared with epoetin alfa or darbepoetin alfa in the treatment of patients with anemia with CKD G5D. This trial is registered with ClinicalTrials.gov: NCT02879305. EudraCT Number: 2016-000541-31; Sponsor Protocol Number: 200807.

[1]  W. Winkelmayer,et al.  Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  M. Nangaku,et al.  Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[3]  F. Tentori,et al.  Combinations of mineral and bone disorder markers and risk of death and hospitalizations in the international Dialysis Outcomes and Practice Patterns Study , 2019, Clinical kidney journal.

[4]  Ajay K. Singh,et al.  Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. , 2019, Current opinion in nephrology and hypertension.

[5]  J. McMurray,et al.  Intravenous Iron in Patients Undergoing Maintenance Hemodialysis , 2019, The New England journal of medicine.

[6]  J. McMurray,et al.  Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data , 2018, American Journal of Nephrology.

[7]  J. Lepore,et al.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis , 2018, Clinical kidney journal.

[8]  Sung Gyun Kim,et al.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease , 2018, Clinical kidney journal.

[9]  M. Nangaku,et al.  Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects , 2016, American Journal of Nephrology.

[10]  V. Haase,et al.  Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. , 2016, Kidney international.

[11]  James E. Novak,et al.  Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[12]  M. Sahay,et al.  A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  A. Rastogi,et al.  Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. , 2016, Journal of the American Society of Nephrology : JASN.

[14]  V. Haase,et al.  Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. , 2012, The Journal of clinical investigation.

[15]  K. Mahaffey,et al.  Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  H. Uno,et al.  Erythropoietic response and outcomes in kidney disease and type 2 diabetes. , 2010, The New England journal of medicine.

[17]  Ajay K. Singh,et al.  Anemia in chronic kidney disease: new advances. , 2010, Heart failure clinics.

[18]  稲荷場 ひろみ,et al.  ESA(erythropoiesis stimulating agent)投与下のヘモグロビン変動についての検討 , 2010 .

[19]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[20]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[21]  R. Califf,et al.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. , 2008, Kidney international.

[22]  C. Stehman-Breen,et al.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[23]  Ashutosh Kumar Singh,et al.  Editorial: The Optimal Hemoglobin in Dialysis Patients— A Critical Review , 2007, Seminars in dialysis.

[24]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[25]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[26]  W. März,et al.  Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics , 2004, Kidney and Blood Pressure Research.

[27]  Gaël Nicolas,et al.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. , 2002, The Journal of clinical investigation.

[28]  Monitor , 2002 .

[29]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.

[30]  J. Adamson,et al.  KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease , 2012 .

[31]  T. Hedner,et al.  Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.

[32]  S. Holm A Simple Sequentially Rejective Multiple Test Procedure , 1979 .